Bill > SB2772

Introduced Session

Reinserts the provisions of the introduced bill, as amended by Senate Amendment No. 2, with the following changes. In a provision concerning the members of the Illinois Psilocybin Advisory Board, provides that if there is a vacancy for any reason, the applicable appointing authority shall appoint an individual to fill the vacancy in a timely manner (rather than appoint an individual to serve as a member in an acting capacity until the individual is approved by the Board as a member of the Board for the remainder of the unexpired term). Provides that the report the Board shall submit to the Governor and the General Assembly shall include an evaluation of (rather than a recommendation on) the medical efficacy of listed psychedelic substances based on medical, psychological, and scientific studies, research, clinical trials in the United States, and other information related to the safety and efficacy of each substance. Removes from the report the necessity to include recommendations concerning whether listed psychedelic substances may be included in an appropriate statutory or regulatory framework to avoid an unregulated de facto market for entheogenic substances other than psilocybin. Provides that the report shall include recommendations on the availability of Medicaid coverage for psilocybin (rather than entheogens) and associated services. Effective immediately.

AI Summary

Committee Categories

Theresa Mah (D)*,  Rachel Ventura (D)*,  Christopher Belt (D),  La Shawn Ford (D),  Graciela Guzmán (D),  Michael Hastings (D),  Mattie Hunter (D),  Emil Jones (D),  Dave Koehler (D),  Mike Porfirio (D),  Willie Preston (D),  Mike Simmons (D),  Karina Villa (D),  Celina Villanueva (D),  Mark Walker (D), 

House Executive Committee Hearing (10:00:00 5/20/2026 Room 114) (on 05/20/2026)

Official Document